Madrigal reports positive results from phase 3 MAESTRO-NAFLD study of resmetirom
HIGH IMPACT – Madrigal reported positive topline data from the double-blind portion of the its phase 3 MAESTRO-NAFLD study of resmetirom in NASH. Patients in the study were identified based on non-invasive imaging and biomarkers, and were treated with either 80mg, 100mg resmetirom once daily or placebo for 52 wks. Safety (969 patients) Safe and well-tolerated […]